Skip to main content
Premium Trial:

Request an Annual Quote

Gene Logic Hires New CEO as Strategy Shift Continues

NEW YORK (GenomeWeb News) – Gene Logic today said it has hired Charles Dimmler as president CEO, replacing Mark Gessler, who will remain chairman of the board.
Gene Logic took the step to help it transition into a purely drug-repositioning business. A milestone in that strategy took place last December when the company sold its preclinical division to San-Francisco-based contract research organization Bridge Pharmaceuticals for $15 million.
Dimmler, 65, has been on the financial and management ends of the biotechnology industry for two decades, and has been a director at Gene Logic for 10 years, according to Gene Logic.

The Scan

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.

Estonian Biobank Team Digs into Results Return Strategies, Experiences

Researchers in the European Journal of Human Genetics outline a procedure developed for individual return of results for the population biobank, along with participant experiences conveyed in survey data.

Rare Recessive Disease Insights Found in Individual Genomes

Researchers predict in Genome Medicine cross-population deletions and autosomal recessive disease impacts by analyzing recurrent nonallelic homologous recombination-related deletions.

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.